OBJECTIVES: For patients with rheumatoid arthritis (RA), convenience, frequency of dosing, and invasiveness vary greatly across different administration routes and may influence their everyday lives. The objective of this study was to investigate the impact of administration method on patients’ quality of life, understand their resulting unmet needs, and establish an overall preference for method of administration for RA treatment. METHODS: Patients from France, UK, Germany, Italy, Spain, Belgium, Sweden, and the Netherlands diagnosed with RA by a physician and taking prescription medication – disease-modifying anti-rheumatic drug (DMARD) monotherapy, biologic monotherapy, or DMARD and biologic combination therapy – completed a 20-minute online survey.  Patients were asked about: 1) benefits and drawbacks of their current treatment administration method; 2) their preference for twice-daily oral therapy versus injection or intravenous (IV) infusion therapy if it met their safety and efficacy expectations; 3) if told by their doctor that they needed to change their current RA therapy, would they switch to twice-daily oral tablets, injections, or IV infusion if efficacy and safety requirements were met.  RESULTS: 1400 patients were included: n=250 patients in each of France, UK, Germany, Italy, and Spain and n=50 in each of Sweden, Belgium, and the Netherlands. Oral DMARDs were seen as having more benefits and fewer drawbacks than DMARD injections, biologic injections, and IV therapy. The majority of patients (79%) would prefer a twice-daily oral tablet than an injection or IV infusion (21%) if it met efficacy and safety expectations. If told by their doctor that they needed to change their current RA therapy, 83% of all patients would prefer switching to twice-daily oral tablets over injection (13%) or IV infusion (4%). CONCLUSIONS: Oral therapy can meet some of the key practical and emotional unmet needs RA patients face with injectable or IV infusion therapy, providing efficacy and safety requirements are met.